Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 37, 2016, Pages 10238-10244

  Liu, Minmin ^a   Ohtani, Hitoshi ^a   Zhou, Wanding ^a   Ørskov, Andreas Due ^b   Charlet, Jessica ^c   Zhang, Yang W ^d   Shen, Hui ^a   Baylin, Stephen B ^a,d   Liang, Gangning ^c   Grønbæk, Kirsten ^b   Jones, Peter A ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

5 hydroxymethylcytosine; DNA methyltransferase inhibitor; Endogenous retrovirus; Epigenetic therapy; Vitamin C

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; ASCORBIC ACID; DECITABINE; DEHYDROASCORBIC ACID; DOUBLE STRANDED RNA; ENZYME; INTERFERON; TEN ELEVEN TRANSLOCATION 2 PROTEIN; UNCLASSIFIED DRUG; AZACITIDINE; DNA BINDING PROTEIN; ENZYME INHIBITOR; METHYLTRANSFERASE; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ASCORBIC ACID DEFICIENCY; CANCER CELL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DEMETHYLATION; DRUG POTENTIATION; ENDOGENOUS RETROVIRUS; GENE EXPRESSION REGULATION; GENE INACTIVATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS TRANSCRIPTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COMPLICATION; DNA METHYLATION; DRUG EFFECTS; FEMALE; GENETICS; HEMATOLOGIC DISEASE; MALE; METABOLISM; PATHOLOGY;

APOPTOSIS; ASCORBIC ACID; ASCORBIC ACID DEFICIENCY; AZACITIDINE; CELL PROLIFERATION; DNA METHYLATION; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENDOGENOUS RETROVIRUSES; ENZYME INHIBITORS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INTERFERONS; MALE; METHYLTRANSFERASES; PROTO-ONCOGENE PROTEINS; RNA, DOUBLE-STRANDED;

EID: 84986903108     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1612262113     Document Type: Article

References (49)

1. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 11(10):726-734.
2. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990):457-463.
3. Sharma S, De Carvalho DD, Jeong S, Jones PA, Liang G (2011) Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. PLoS Genet 7(2):e1001286.
4. Ghoshal K, et al. (2005) 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 25(11): 4727-4741.
5. Bender CM, et al. (1999) Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol 19(10):6690-6698.
6. Yang X, et al. (2014) Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 26(4):577-590.
7. Kantarjian H, et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106(8):1794-1803.
8. Kantarjian HM, et al. (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670-2677.
9. Fenaux P, et al.; International Vidaza High-Risk MDS Survival Study Group (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10(3):223-232.
10. Fenaux P, et al. (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28(4):562-569.
11. Issa JP, et al. (2015) Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: A multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol 16(9):1099-1110.
12. Chiappinelli KB, et al. (2015) Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162(5):974-986.
13. Roulois D, et al. (2015) DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162(5):961-973.
14. Lee YG, et al.; Korean Society of Haematology AML/MDS working party (2013) Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. Br J Haematol 161(3):339-347.
15. Schecter J, Galili N, Raza A (2012) MDS: Refining existing therapy through improved biologic insights. Blood Rev 26(2):73-80.
16. Balch C, Nephew KP (2013) Epigenetic targeting therapies to overcome chemotherapy resistance. Adv Exp Med Biol 754:285-311.
17. Wrangle J, et al. (2013) Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4(11):2067-2079.
18. Blaschke K, et al. (2013) Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 500(7461):222-226.
19. Tahiliani M, et al. (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929):930-935.
20. Pastor WA, Aravind L, Rao A (2013) TETonic shift: Biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol 14(6):341-356.
21. Pfeifer GP, Kadam S, Jin SG (2013) 5-hydroxymethylcytosine and its potential roles in development and cancer. Epigenetics Chromatin 6(1):10.
22. Chung TL, et al. (2010) Vitamin C promotes widespread yet specific DNA demethylation of the epigenome in human embryonic stem cells. Stem Cells 28(10):1848-1855.
23. Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J (2008) Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 61(5):759-766.
24. Tsai HC, et al. (2012) Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21(3):430-446.
25. Bender CM, Pao MM, Jones PA (1998) Inhibition of DNA methylation by 5-aza-2?-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 58(1):95-101.
26. Yun J, et al. (2015) Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science 350(6266):1391-1396.
27. Ma Y, et al. (2014) High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6(222):222ra18.
28. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621-681.
29. Karpf AR, Moore BC, Ririe TO, Jones DA (2001) Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2?-deoxycytidine. Mol Pharmacol 59(4):751-757.
30. Karpf AR, et al. (2004) Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2?-deoxycytidine. Mol Pharmacol 65(1):18-27.
31. Dunn CA, Romanish MT, Gutierrez LE, van de Lagemaat LN, Mager DL (2006) Transcription of two human genes from a bidirectional endogenous retrovirus promoter. Gene 366(2):335-342.
32. Walsh CP, Chaillet JR, Bestor TH (1998) Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat Genet 20(2):116-117.
33. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR (2006) Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol 80(10):5059-5064.
34. Schleicher RL, Carroll MD, Ford ES, Lacher DA (2009) Serum vitamin C and the prevalence of vitamin C deficiency in the United States: 2003-2004 National Health and Nutrition Examination Survey (NHANES). Am J Clin Nutr 90(5):1252-1263.
35. Mayland CR, Bennett MI, Allan K (2005) Vitamin C deficiency in cancer patients. Palliat Med 19(1):17-20.
36. Huijskens MJ, Wodzig WK, Walczak M, Germeraad WT, Bos GM (2016) Ascorbic acid serum levels are reduced in patients with hematological malignancies. Results Immunol 6:8-10.
37. Nannya Y, Shinohara A, Ichikawa M, Kurokawa M (2014) Serial profile of vitamins and trace elements during the acute phase of allogeneic stem cell transplantation. Biol Blood Marrow Transplant 20(3):430-434.
38. Dahl H, Degré M (1976) The effect of ascorbic acid on production of human interferon and the antiviral activity in vitro. Acta Pathol Microbiol Scand [B] 84B(5):280-284.
39. Kim Y, et al. (2013) Vitamin C is an essential factor on the anti-viral immune responses through the production of interferon-alpha/beta at the Initial stage of influenza A virus (H3N2) infection. Immune Netw 13(2):70-74.
40. Linster CL, Van Schaftingen E (2007) Vitamin C. Biosynthesis, recycling and degradation in mammals. FEBS J 274(1):1-22.
41. Amadori S, Fenaux P, Ludwig H, O'dwyer M, Sanz M (2005) Use of arsenic trioxide in haematological malignancies: Insight into the clinical development of a novel agent. Curr Med Res Opin 21(3):403-411.
42. Michel L, et al. (2003) Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: Evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). J Invest Dermatol 121(4):881-893.
43. Hoffer LJ, et al. (2008) Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19(11):1969-1974.
44. Bejanyan N, et al. (2012) A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer 118(16):3968-3976.
45. Bestor TH, Tycko B (1996) Creation of genomic methylation patterns. Nat Genet 12(4): 363-367.
46. Liang G, et al. (2002) Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol 22(2):480-491.
47. Jones PA, Liang G (2009) Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 10(11):805-811.
48. Patel K, et al. (2010) Targeting of 5-aza-2?-deoxycytidine residues by chromatinassociated DNMT1 induces proteasomal degradation of the free enzyme. Nucleic Acids Res 38(13):4313-4324.
49. Snyder A, et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189-2199.